Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicenter, Non-Randomized Study of the Efficacy and Safety of Enfortumab Vetodin in Combination With Pembrolizumab Previously Treated Advanced Melanoma

NCT06906822 is registered in ClinicalTrials.gov with Grupo Español Multidisciplinar de Melanoma as lead sponsor.

NCT NCT06906822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06906822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicenter, Non-Randomized Study of the Efficacy and Safety of Enfortumab Vetodin in Combination With Pembrolizumab Previously Treated Advanced Melanoma
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 10, 2025
Completion date
June 30, 2028
Enrollment
60 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma